Phaseline

Targets › SLCO1B1

SLCO1B1 (Solute carrier organic anion transporter family member 1B1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Oncology; next expected readout Dec 2026.

Mediates the Na(+)-independent uptake of organic anions. Shows broad substrate specificity, can transport both organic anions such as bile acid taurocholate (cholyltaurine) and conjugated steroids (dehydroepiandrosterone 3-sulfate, 17-beta-glucuronosyl estradiol, and estrone 3-sulfate), as well as eicosanoids (prostaglandin E2, thromboxane B2, leukotriene C4, and leukotriene E4), and thyroid hormones…. (UniProt, Q9Y6L6)

Open in Phaseline: the race on SLCO1B1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Fujian Medical University Union HospitalSilibinin
Hepatoprotective agent; inhibits cancer cell growth and differentiation; stabilizes hepato
SLCO1B1Phase 4Acute Myeloid LeukemiaDec 2026

Conditions

Acute Myeloid Leukemia (1)

Modalities

small molecule (1)

Companies

Fujian Medical University Union Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.